OBI Osta Biotechnologies Inc.

THE ISSUE OF THIS PRESS RELEASE IS LIMITED TO CANADA ONLY. THIS PRESS RELEASE
SHOULD NOT BE ISSUED IN THE UNITED STATES THROUGH U.S. NEWS WIRE AGENCIES.


Osta Biotechnologies Inc. (TSX VENTURE:OBI) today announced that it has received
a Notice of Allowance from the U.S. patent & trademark office for one of the key
patents entitled "Use of PEX in the treatment of metabolic bone diseases". The
company is advancing the preclinical development of a novel class of therapeutic
agents for the treatment of osteoporosis by promoting bone formation based on
PEX inhibition. To date, the company has obtained promising preclinical results
on the safety and effectiveness of its lead molecule OB-14, a safe and effective
small molecule therapeutic agent for the treatment of osteoporosis.


PHEX, formerly PEX (phosphate regulating gene with homologies to endopeptidases
on the X chromosome) enzyme is a metalloendopeptidase which is found almost
exclusively on the surface of bone forming cells called osteoblasts. Osta's
researchers have shown that through proteolytic cleavage, osteoblast
membrane-bound PHEX degrades Parathyroid hormone, PTH (1-34). Other researchers
have shown that PHEX also cleaves Parathyroid hormone related peptide (PTHrP).
PTH and PTHrP are known to stimulate the bone-forming activities of osteoblasts
and are important for normal skeletal maintenance. The pre-clinical results
obtained to date by Osta's researchers have clearly demonstrated that OB-14 is
not only safe, but is also very effective in increasing local microenvironmental
concentration of PTHrP in osteoblasts and leads to bone formation in mice
treated with OB-14 daily for a period of 60 days. In addition, no significant
toxicity or changes in the phosphate levels were noted in mice treated with
OB-14 over a period of 60 days. Dr. Andrew Karaplis, President and Chief
Scientific Officer of Osta commented "our results are truly exciting and clearly
demonstrate that by inhibiting PHEX, and hence by modulating the
micro-environmental concentrations of critical bone anabolic agents, namely PTH
and/or PTHrP, it may be possible to present a novel strategy for the treatment
of metabolic bone diseases such as osteoporosis".


Osta Biotechnologies Inc.

Osta is a biopharmaceutical company listed on the TSX Venture Exchange dedicated
to developing novel diagnostics and therapeutics in the areas of Cancer,
Alzheimer's disease, Osteoporosis, X-linked hypophosphatemic rickets (XLH) and
Osteoarthritis.


Certain information in this press release is forward-looking and is subject to
numerous risks and uncertainties. By their nature, such forward-looking
statements involve risks and uncertainties that could cause actual results to
differ materially from those contemplated by the forward-looking statements.
These risks include actions of Osta's competitors, and those inherent in
scientific research and development.

Grafico Azioni Osta Biotechnologies Inc. (TSXV:OBI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Osta Biotechnologies Inc. (TSXV:OBI)
Storico
Da Giu 2023 a Giu 2024